Result: Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2022

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

Cancers. - 14, 3 (2022) , 540, ISSN: 2072-6694

*DOI*:

10.3390/cancers14030540

*Result*: Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy